English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor:We agree with Professor Weintraub that there are uncertainties about the treatment of patients with recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke. Many physicians are uncertain whether the benefits of treatment outweigh the potentials harms1 and so do not provide treatment in their areas. Hence, the provision of thrombolysis is patchy in some countries—in the UK only 33 centers …

Uncertainties About Thrombolysis for Stroke Should Be Addressed With Large-Scale Randomized Trials